StockNews.AI
AKRO
StockNews.AI
118 days

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

1. Moore Law is investigating Akero for potential misrepresentations to investors. 2. 20% of SYMMETRY study patients' NASH status was unverified. 3. Akero's stock dropped 62.61% after disappointing trial data announcement. 4. Investors may seek damages, emphasizing potential corporate governance reforms. 5. Shareholders' claims could impact Akero's future market position.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The substantial drop in stock price indicates severe investor trust issues and potential liabilities, similar to historical cases like Valeant Pharmaceuticals, which faced stock collapse post-investigation announcements.

How important is it?

The ongoing investigation into misrepresentations directly threatens Akero's market credibility and stock price, indicating a high likelihood of impact.

Why Short Term?

The immediate aftermath of litigation investigations will likely lead to further stock volatility, as seen in other biotech companies facing similar scrutiny.

Related Companies

VRTXSGENPFE
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) Shareholders should email Fletcher@fmoorelaw.com; please contact only if shares acquired before September 13, 2022 The investigation concerns misrepresentations to investors as to the true nature of the patient population that was being tested in Akero's SYMMETRY study. Specifically, despite telling investors that the study's patient population was limited to those with NASH induced cirrhosis (a fact that was key for data integrity and the likelihood of study success), for approximately 20% of those being tested Akero had not confirmed that the patients had NASH and that NASH had in fact caused their cirrhosis. Akero shocked the market on October 10, 2023 when the company posted disappointing interim data from its Phase 2b SYMMETRY trial for EFX. Specifically, Akero stated that 22% (28mg) and 24% (50mg) of those on EFX and 14% on placebo indicated at least one stage improvement in fibrosis with no worsening of NASH at week 36, the trial's primary endpoint, but that these changes were not statistically significant. In addition, Akero added that 12 patients, including 11 in EFX groups, discontinued the trial due to drug-related adverse events. On this news, Akero's stock price fell $30.39 per share, or 62.61%, to close at $18.15 per share on October 10, 2023. If you own Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO), please contact Fletcher Moore by email at fletcher@fmoorelaw.com or (212) 709-8245. You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. MOORE LAW PLLC30 Wall Street, 8th FloorNew York, NY 10005(212) 709-8245fletcher@fmoorelaw.comwww.fmoorelaw.com

Related News